CMS’ Limited Resources Hinder Ability To Implement Value-Based Purchasing
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Medicare & Medicaid Services' inability to fairly and accurately determine the "value" of a new device could deter the agency from utilizing value-based purchasing to pay for new technologies, according to MedPAC staff member Chantal Worzala, PhD
You may also be interested in...
New Technology Payment Rates Should Reflect Quality Of Life, Cost – Panel
CMS should consider a new medical technology's cost as well as its impact on quality of life in setting Medicare payment rates, according to an expert panel convened by Project HOPE
MedPAC Looking At Alternate Payment Mechanisms For New Technology
The Medicare Payment Advisory Commission is finding that coverage and cost components in paying for new medical technologies cannot be easily separated
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.